Roche Rolls Out HPV Self-Sampling for Cervical Cancer Screening

Roche has launched a human papillomavirus (HPV) self-sampling solution in EU countries.
 
Using the tool, patients can privately collect samples for HPV screening at their healthcare facility after instructions by a clinician. The clinically-validated vaginal sample is then analyzed using the Roche cobas HPV test on a Roche molecular instrument.
 
HPV screening helps identify those at risk of developing cervical cancer to facilitate early treatment. Roche’s self-sampling tool helps reduce the barriers of limited access to testing, past experiences, embarrassment, and cultural influences, while also generating accurate and reliable results.
 
“The elimination of cervical cancer is within reach. Reducing barriers to HPV screening by enabling women to self-collect their own specimen for HPV testing is a critical tool in the fight against cervical cancer,” Thomas Schinecker, CEO of Roche Diagnostics told the press.
 
The cobas HPV test is used for routine cervical cancer screening per professional medical guidelines, including HPV primary screening, co-testing (or adjunctive screen) with cytology, and for triage of patients with abnormal cytology to assess cervical precancer and cancer risks.